Return to content in this issue


ARADyAL: The Spanish Multidisciplinary Research Network for Allergic Diseases

Torres MJ1-4, Agundez J5, Barber D6, Bartra J7,8, Davila I9, Escribese MM10, Fernandez-Rivas M11, Ferrer M12, Perez-Inestrosa E3,13, Villalba M14, Mayorga C1-3

1Allergy Research Group, Instituto de Investigación Biomédica de Málaga-IBIMA, ARADyAL, Málaga, Spain
2Allergy Clinical Unit, Hospital Regional Universitario de Málaga, Málaga, Spain
3Centro Andaluz de Nanomedicina y Biotecnología-BIONAND, Málaga, Spain
4Medicine Department, Universidad de Málaga-UMA, Málaga, Spain
5University Institute of Molecular Pathology Biomarkers, UEx, Cáceres; ARADyAL Instituto de Salud Carlos III, Spain
6School of Medicine, Institute for Applied Molecular Medicine, Universidad CEU San Pablo, Madrid, Spain
7Allergy Section, Pneumology Department, Institut Clínic Respiratori (ICR), Hospital Clínic de Barcelona, Barcelona, Spain
8Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain
9Allergy Service, University Hospital of Salamanca, Department of Biomedical and Diagnostics Sciences, School of Medicine, University of Salamanca, Institute for Biomedical Research of Salamanca (IBSAL), Salamanca, Spain
10School of Medicine, Department of Basic Medical Sciences, Universidad CEU San Pablo, Madrid, Spain
11Allergy Department, Hospital Clinico San Carlos, Universidad Complutense, IdISSC, ARADyAL, Madrid, Spain
12Department of Allergy and Clinical Immunology, Clinica Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain
13Departamento de Química Orgánica, Universidad de Málaga-IBIMA, Málaga, Spain
14Biochemistry and Molecular Biology Department, Facultad de Ciencias Químicas, Universidad Complutense de Madrid, Madrid, Spain

J Investig Allergol Clin Immunol 2021; Vol 31(2) : 108-119
doi: 10.18176/jiaci.0629

Thematic cooperative health research networks (RETICS) are organizational structures promoted by the Instituto de Salud Carlos III of the Spanish Ministry of Science with the objective of carrying out cooperative research projects addressing challenges of general interest for society as a whole in the field of health care. The RETICS of Asthma, Adverse Drug Reactions, and Allergy (ARADyAL) received funding in 2016 for a 5-year program (2017-2021). ARADyAL integrates basic and clinical research in the areas of allergy, immunology, genetics, nanomedicine, pharmacology, and chemistry, with special interest in research on new biomarkers and the design and evaluation of new interventions for allergic patients with severe phenotypes.
The consortium comprises 28 groups across Spain, including 171 clinical and basic researchers, 17 clinical groups that cover more than 10 000 000 patients of all ages from urban and rural areas and 11 basic groups active mostly at universities and research institutes. ARADyAL has proposed a research program organized into 3 different areas focusing on precision medicine, as follows: Program 1, Mechanisms and prediction of adverse drug reactions and allergic diseases; Program 2, Toward a precise diagnosis of allergic diseases; and Program 3, Predicting interventions in allergic diseases. There is also 1 common program dedicated to training. The network has a Steering Committee and an External Advisory Scientific Committee, which advise the global network coordinator, who has recognized expertise in the field. ARADyAL is a unique meeting point for clinicians and basic scientists who are already working in allergy.

Key words: Allergy, Research, Networks, Biomarkers, Mechanism, Diagnosis, Treatment

Title Type Size
10.18176_jiaci.0629_material-suppl.pdf pdf 303.05 Kb